Direkt zum Inhalt

Pal, Sumanta K. ; Somford, Diederik M. ; Grivas, Petros ; Sridhar, Srikala S. ; Gupta, Shilpa ; Bellmunt, Joaquim ; Sonpavde, Guru ; Fleming, Mark T. ; Lerner, Seth P. ; Loriot, Yohann ; Hoffman-Censits, Jean ; Valderrama, Begoña P. ; Andresen, Corina ; Schnabel, Marco J. ; Cole, Suzanne ; Daneshmand, Siamak

Targeting FGFR3 alterations with adjuvant infigratinib in invasive urothelial carcinoma: the phase III PROOF 302 trial

Article

Pal, Sumanta K., Somford, Diederik M., Grivas, Petros, Sridhar, Srikala S., Gupta, Shilpa, Bellmunt, Joaquim, Sonpavde, Guru, Fleming, Mark T., Lerner, Seth P., Loriot, Yohann, Hoffman-Censits, Jean, Valderrama, Begoña P., Andresen, Corina, Schnabel, Marco J., Cole, Suzanne and Daneshmand, Siamak (2022) Targeting FGFR3 alterations with adjuvant infigratinib in invasive urothelial carcinoma: the phase III PROOF 302 trial. Future Oncology 18 (21), pp. 2599-2614.



Involved Institutions


Details

Item typeArticle
Journal or Publication TitleFuture Oncology
PublisherFUTURE MEDICINE LTD
Place of PublicationLONDON
Volume18
Number of Issue or Book Chapter21
Page Rangepp. 2599-2614
Date2022
Date of publication29 Feb 2024 13:01
InstitutionsMedicine > Lehrstuhl für Urologie
Identification Number
ValueType
10.2217/fon-2021-1629DOI
KeywordsCELL-CARCINOMA; BLADDER; FUSIONS; BGJ398; ASSOCIATION; GUIDELINES; INHIBITOR; REVEALS; adjuvant cisplatin-based chemotherapy; adjuvant therapy; cisplatin-therapy refusal; FGFR3; FGFR inhibitor; fusions or rearrangements; infigratinib; muscle-invasive urothelial carcinoma; mutations; neoadjuvant cisplatin-based chemotherapy; phase III; PROOF 302; upper tract urothelial carcinoma; urothelial bladder carcinoma; urothelial carcinoma
Dewey Decimal Classification600 Technology > 610 Medical sciences Medicine
StatusPublished
RefereedYes, this version has been refereed
Created at the University of RegensburgPartially
Item ID57677

Export bibliographical data

Owner only: item control page

nach oben